STOCK TITAN

If You Invested in Cadrenal Therapeutics, Inc. (CVKD)

Healthcare · Biotechnology · NASDAQ
Looking for the current price? See the CVKD quote & overview
$1,000 invested 1 Year Ago
$150
-85.0% price return
-85.0% with dividends reinvested
Bought on Nov 20, 2025 at $11.30 split-adjusted
$1,000 invested 5 Years Ago
N/A
Our prices start Jan 20, 2023
$1,000 invested 10 Years Ago
N/A
Our prices start Jan 20, 2023

What $1,000 or $10,000 in CVKD Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Jan 20, 2023
$1,000 $150 -85% — — $27 -97%
$10,000 $1,496 -85% — — $273 -97%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-19. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for CVKD

$1,000 Investment Over Time

CVKD vs S&P 500

Year-by-Year Returns

CVKD annual performance
Year Start Price End Price Annual Return Cumulative
2023Jan 20 to Dec 29 $61.80 $11.10 -82.0% -82.0%
2024 $11.10 $14.49 +30.6% -76.6%
2025 $14.49 $6.78 -53.2% -89.0%
2026Dec 31, 2025 to Nov 19 $6.78 $1.69 -75.1% -97.3%

About Cadrenal Therapeutics, Inc.

Healthcare · NASDAQ

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a biopharmaceutical company focused on developing novel anticoagulant therapies that address critical gaps in both acute and chronic anticoagulation management for rare and high‑risk patient populations. According to the company’s disclosures, its pipeline is built around differentiated drug candidates intended to provide greater predictability, stability, and control than many existing blood thinners for patients who do not respond well to current standards of care.

Business focus and therapeutic area

Cadrenal describes its mission as developing biopharmaceutical products that bridge gaps in current anticoagulant therapy. Its programs target areas where conventional anticoagulation may not provide sufficient safety or efficacy, particularly in patients with complex cardiovascular conditions, kidney dysfunction, or immune‑mediated thrombotic disorders. The company’s work is situated within the broader anticoagulation market, with repeated references in its public communications to a large global opportunity and underserved, high‑risk subpopulations.

Clinical‑stage pipeline

Cadrenal reports three clinical‑stage assets in development:

  • VLX‑1005 – A first‑in‑class, Phase 2, parenteral 12‑lipoxygenase (12‑LOX) inhibitor being developed for patients with heparin‑induced thrombocytopenia (HIT). Company materials describe VLX‑1005 as a potent, highly selective small‑molecule inhibitor of human 12‑LOX, a pathway associated with immune platelet‑mediated inflammation and thrombosis in HIT. VLX‑1005 has received Orphan Drug Designation and Fast Track designation from the U.S. Food and Drug Administration (FDA), as well as orphan drug status from the European Medicines Agency, for the treatment of HIT.
  • Tecarfarin – An oral vitamin K antagonist (VKA) anticoagulant for chronic use. Cadrenal characterizes tecarfarin as a late‑stage or Phase 3‑ready investigational product with the same general mechanism of action as warfarin but with a different metabolic pathway. Company descriptions state that tecarfarin is designed to address unmet needs in anticoagulation therapy, particularly in patients with end‑stage kidney disease and atrial fibrillation (ESKD+AFib) and in those with left ventricular assist devices (LVADs). Tecarfarin has received FDA Orphan Drug Designation and Fast Track designation for prevention of systemic thromboembolism of cardiac origin in ESKD+AFib, and Orphan Drug Designation for prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including LVADs.
  • Frunexian – A parenteral small‑molecule Factor XIa (FXIa) antagonist intended for acute hospital settings. Company disclosures describe frunexian as a Phase 2‑ready intravenous Factor XIa inhibitor designed for situations where contact activation of coagulation by medical devices is important, such as cardiopulmonary bypass, catheter thrombosis, and other blood‑contacting implanted cardiac devices. Cadrenal positions frunexian for use in complex cardiac surgery (including coronary artery bypass grafting) and continuous renal replacement therapy (CRRT) environments.

Across these programs, Cadrenal emphasizes a focus on both chronic and acute care settings, with tecarfarin aimed at long‑term anticoagulation and frunexian and VLX‑1005 directed toward high‑acuity hospital‑based indications.

Regulatory designations and development stage

Cadrenal highlights multiple regulatory designations across its portfolio. Tecarfarin has Orphan Drug Designation and Fast Track designation for ESKD patients with atrial fibrillation and Orphan Drug Designation for LVAD patients. VLX‑1005 holds Orphan Drug Designation and Fast Track designation from the FDA for HIT and orphan drug status from the European Medicines Agency. Company communications describe VLX‑1005 as having completed Phase 1 studies in healthy participants and a Phase 2 study in individuals with suspected HIT, with interim data suggesting reductions in thromboembolic events. Frunexian is described as Phase 2‑ready following Cadrenal’s acquisition of a Factor XIa inhibitor portfolio.

Strategic positioning within anticoagulation

In its public statements, Cadrenal repeatedly characterizes its strategy as targeting rare and high‑risk patients who face limitations with existing anticoagulants. This includes patients with end‑stage kidney disease, those with implanted mechanical circulatory support devices, and individuals with immune‑mediated complications such as HIT. The company’s materials describe a portfolio that spans chronic oral therapy, acute parenteral therapy, and immune‑mediated thrombotic conditions, with the goal of addressing areas where current anticoagulants may be inadequate.

Stock listing and corporate status

Cadrenal Therapeutics, Inc. is incorporated in Delaware and its common stock is listed on The Nasdaq Capital Market under the symbol CVKD, as indicated in its SEC filings. The company identifies itself as an emerging growth company under applicable U.S. securities regulations. Its SEC reports and press releases reference ongoing clinical development activities, portfolio acquisitions, and capital‑raising transactions, reflecting an early‑stage, development‑focused biopharmaceutical profile.

Market Cap
$7.0M
Current Price
$1.69
EPS (FY2025)
-$6.64
View full CVKD overview

Frequently Asked Questions

Cadrenal Therapeutics, Inc. investment returns

How much would $1,000 invested in Cadrenal Therapeutics, Inc. be worth today?

If you invested $1,000 in Cadrenal Therapeutics, Inc. (CVKD) 1 year ago on 2025-11-20, your investment would be worth $150 as of 2026-11-19, a -85.0% price return without dividends.

Has Cadrenal Therapeutics, Inc. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare CVKD performance over available time periods.

What is Cadrenal Therapeutics, Inc.'s average annual return?

Over the past 1 year, CVKD’s share price returned -85.0%, without dividends. Individual years vary a great deal, and CVKD’s best recent full year was 2024 (+30.6%) while the worst was 2025 (-53.2%).

For informational and educational purposes only, not investment advice.